

Journal Pre-proof

Italian version of Cancer Dyspnea Scale: cultural-linguistic and clinical validation in patients with advanced cancer disease in palliative care settings.



Stefania Tinti, MSc, RN, Beatrice De Maria, PhD, MSc, Monica Parati, MSc, Stefano Terzoni, PhD, MSc, RN, Maria Cristiana Rossi, RN, Daria Da Col, MSc, RN, Giulia Pairona, MSc, RN, Carla Longhi, MD, Elisa Giudici, RN, Irene Pidone, RN, Annalisa Alberti, MSc, RN, Michele Sofia, MD, Ida Ramponi GM, Nicla Urbano, MSc, RN, Keiko Tanaka, MD, PhD, Anne Destrebecq, MSc, RN

PII: S0885-3924(20)30803-4

DOI: <https://doi.org/10.1016/j.jpainsymman.2020.10.008>

Reference: JPS 10682

To appear in: *Journal of Pain and Symptom Management*

Received Date: 13 July 2020

Revised Date: 6 October 2020

Accepted Date: 8 October 2020

Please cite this article as: Tinti S, De Maria B, Parati M, Terzoni S, Rossi MC, Da Col D, Pairona G, Longhi C, Giudici E, Pidone I, Alberti A, Sofia M, Ramponi GM I, Urbano N, Tanaka K, Destrebecq A, Italian version of Cancer Dyspnea Scale: cultural-linguistic and clinical validation in patients with advanced cancer disease in palliative care settings., *Journal of Pain and Symptom Management* (2020), doi: <https://doi.org/10.1016/j.jpainsymman.2020.10.008>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine

Italian version of Cancer Dyspnea Scale: cultural-linguistic and clinical validation in patients with advanced cancer disease in palliative care settings.

Stefania Tinti MSc, RN ¹, **Beatrice De Maria** PhD, MSc ², **Monica Parati** MSc ³, **Stefano Terzoni** PhD, MSc, RN ⁴, **Maria Cristiana Rossi** RN ⁵, **Daria Da Col** MSc, RN ⁶, **Giulia Pairona** MSc, RN ⁶, **Carla Longhi** MD ⁷, **Elisa Giudici** RN ⁷, **Irene Pidone** RN ⁷, **Annalisa Alberti** MSc, RN ⁸, **Michele Sofia** MD ⁵, **Ida Ramponi** GM ⁹, **Nicla Urbano** MSc, RN ⁹, **Keiko Tanaka** MD, PhD ¹⁰, **Anne Destrebecq** MSc, RN ¹¹

¹ Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy,

² IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy,

³ Neuroengineering and Medical Robotics Laboratory, Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy

⁴ ASST- Santi Paolo e Carlo, University of Milan, Milan, Italy,

⁵ ASST-Rhodense, Garbagnate Milanese (Milan), Italy, Palliative Care, Hospice and Pain Therapy Department,

⁶ ASST Grande Ospedale Metropolitano Niguarda (Milan), Italy, Palliative Care – Hospice,

⁷ ASST-Lariana, Mariano Comense (Como), Italy, Palliative Care – Hospice,

⁸ ASST-Rhodense Bachelor School of Nursing, University of Milan, Rho (Milan), Italy,

⁹ ASST-Rhodense, Garbagnate Milanese (Milan), Italy,

¹⁰ Palliative Care Department Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo

¹¹ Department of Biomedical Sciences for Health, University of Milan, Milan, Italy

Corresponding Author: Stefania Tinti, Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy, ASST-Rhodense Bachelor School of Nursing, University of Milan, 1, Legnano Street, Rho (Milan), 20017, Italy. E-mail: stefania.tinti@unimi.it

Running Title: **Italian version of Cancer Dyspnea Scale.**

Summary conflict of interest statements: The authors declare no conflicts of interest relevant to this work.

Disclosures. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data statement. Data are available upon reasonable request to the corresponding author.

Tables: 6; Figures: 0. Appendix: 2; References: 35.

Word count for abstract: 250

Word count for body of text: 2677

Journal Pre-proof

ABSTRACT

Context: The Cancer Dyspnea Scale (CDS) is a self-reported multidimensional tool used for the assessment of dyspnea, a subjective experience of breathing discomfort, in cancer patients. The scale describes dyspnea using three distinct factors: physical, psychological and discomfort at rest. **Objective:** to cross-cultural validate the Italian version of CDS (CDS-IT) and examine its content validity, feasibility, internal consistency and construct validity in patients with advanced cancer. **Methods:** A cross-sectional study was conducted. CDS-IT was forward-backward translated, and its content was validated among a group of experts. Cronbach's α coefficients was used to assess the internal consistency. Construct validity was examined in terms of structural validity through confirmatory factor analysis and convergent validity with Dyspnea Visual Analogue Scale (VAS-D) through the Pearson's correlation coefficient (r). Cancer Quality of life (EORTC QLQ-C15-PAL) and Italian Palliative Outcome Scale (IPOS) were also tested. **Results:** The CDS-IT was cross-cultural validated and showed satisfactory content validity. A total of 101 patients (mean age: 76 (SD 12), 53% of female) were recruited in palliative care settings. CDS-IT reported a good internal consistency in the total score and its factors ($\alpha=0.74-0.83$). The factor analysis corresponded acceptably, but not completely with the original study. CDS-IT strongly correlated with VAS-D ($r=0.68$) and moderately with IPOS and EORTC QLQ-C15-PAL ($r=0.33-0.36$, respectively). **Conclusions:** The study findings supported the cross-cultural validity of the CDS-IT. Its feasibility, internal consistency and construct validity are satisfactory for clinical practice. The CDS-IT is available to healthcare professionals as a useful tool to assess dyspnea in cancer patients.

Keywords: Dyspnea, Cancer Dyspnea Scale, Palliative care, Psychometric properties, Advanced disease

Key Message: The Italian version of Cancer Dyspnea Scale (CDS-IT), a multidimensional self-reported outcome to assess dyspnea was cross-validated. Its internal consistency and construct validity were demonstrated to be satisfactory for clinical practice in palliative care; the scale is a useful tool to self-report dyspnea-related symptoms in patients with advanced cancer.

INTRODUCTION

Dyspnea (or breathlessness) is defined as “a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity”.(1) Prevalence is quite high (>60%) among subjects with advanced diseases, particularly of the heart or lungs.(2-6) Dyspnea worsens before death (7) and compromises the quality of life.(8) In patients with advanced cancer, dyspnea is one of the main symptoms and its measurement essential.(9) The Cancer Dyspnea Scale (CDS) is a multidimensional tool for the detection of dyspnea in cancer patients, developed in Japanese by Dr. Tanaka K.(10) The scale is a feasible and easy-to-use self-reported outcome measure (10), designed to evaluate the physiological and psychological discomfort associated with dyspnea. CDS was validated on consecutive outpatients and inpatients admitted to a Japanese Hospital.(10) Adequate psychometric properties including construct validity, inter-subscale correlation, convergent validity, internal consistency, and test-retest reliability were demonstrated.(10) CDS was later cross-cultural validated in English (10, 11), in Swedish (12) and in Hindi and Marathi.(13) These studies, all recruiting advanced lung cancer patients, found comparable psychometric properties to the original version.(10-13) The aim of this study was to translate and cross-validate the CDS into Italian (i.e. CDS-IT) and test its feasibility, content-validity, internal-consistency, as well as its construct validity on patients with advanced cancer.

METHODS

This cross-sectional study was approved by the Ethics Committee (Number 491-102018 05/10/2018). The participation was voluntary and anonymity was ensured and participants gave their informed written consent. The study was conducted in accordance with Italian law and the principles of the Helsinki Declaration. The study is structured according to the following three phases to develop and test the CDS-IT: phase one (cultural and linguistic validation), phase two (content validation among a group of experts), phase three (examination of feasibility, internal consistency and construct validity on patients with advanced cancer).

Phase I. Cultural and linguistic validation.

The original CDS scale was translated into Italian (CDS-IT) with permission to translate and use the questionnaire obtained from the author of the original version. The forward-backward translation method was adopted.(14) A group of experts in palliative care conducted a formal review of the translated version, improving linguistic and cultural comprehensibility. This version was then back-translated into English, compared to original English version published by Tanaka et al. (10) and validated by Uronis et al. (11) and finally approved by the original author Tanaka K.

Phase II. Content validity among a group of expert.

The CDS-IT was delivered to a group of nine experts in palliative care to assess their agreement regarding how pertinent each item in relation to the objective of its measurement is. The quantitative measure of Content Validity Ratio (CVR) and Index (I-CVIs and S-CVI) was computed.(15, 16)

Phase III. Examination of feasibility, internal consistency and construct validity on patients with advanced cancer.

The CDS-IT was administered to consecutive patients in three hospice or home palliative care settings by trained nurses. Eligibility criteria were: age 18 years or older, intact cognition (score at Mini-Mental State Examination higher than 24), (17) and Glasgow Coma Scale (GCS) with best response, diagnosis of advanced cancer and presence of dyspnea at enrolment and/or in the previous days. Patients whose clinical conditions do not allow to self-report the questionnaire were excluded. Patients who did not speak Italian language were excluded. Eligible participant completed the assessment in a single occasion. Socio-demographic and clinical information were collected. Participants were then asked to complete the CDS-IT. The time for the administration and the difficulties in the comprehension of the items were recorded to assess its feasibility. The CDS-IT is a questionnaire composed of 12 items, with a 5-point scale ranging from 1 (not at all) to 5 (very much). The scale is subdivided in three factors: physical Factor 1 (sense of effort), psychological Factor 2 (sense of anxiety), and Factor 3 reflecting the uncomfortable feeling at rest (sense of discomfort). The maximum total score is 48, with up to 20 points for effort, 16 for anxiety, and 12 for discomfort. A higher score reflects a higher severity of dyspnea.(10) The following measures has been collected to assess construct validity with the CDS-IT and its three factors. Karnofsky Performance Status (KPS) (18-21) was performed to assess illness severity, VAS-D was administered to quantify dyspnea distress.(22, 23) Furthermore, values of peripheral oxygen saturation (SpO₂) were recorded (Philips SureSigns VS2).(24) The quality of life scale developed by the European Organization for Research and Treatment of Cancer quality of life group (EORTC QLQ-C15-PAL) was used to assess the quality of life in cancer research and includes functional, symptoms and global quality of life.(25-27) Finally, we used the Italian Palliative Care Outcome Scale (IPOS) (28-31) to evaluate the physical, psychological symptoms and other dimensions typically assessed in palliative care.(32)

Statistical Analysis.

Sample size was chosen according to the Consensus based Standards for the selection of health Measurements Instruments (COSMIN).(33) A minimum sample size of 100 participants is needed to have a study with a very good quality for the evaluation of reliability and validity.(33) Therefore, 101 participants were enrolled in this study.

Descriptive statistics were used to summarize data. Continuous variables were presented as mean (standard deviation, SD) and categorical variables were presented as percentage (absolute value). Cronbach's alpha, Cronbach's alpha if the item was deleted and the corrected item-total correlation were computed for the CDS-IT total score and its subscale to assess the internal consistency and homogeneity of the questionnaire items. Cronbach's alpha higher than 0.7 and corrected item-total correlations greater than 0.3 were considered adequate. To assess the structural validity, confirmatory factor analysis with Varimax rotation was conducted. Convergent validity was assessed by Pearson's correlations with VAS-D. To examine the multidimensional aspects of dyspnea, correlations between CDS-IT and the other assessment measures (SpO₂, EORTC QLQ-C15-PAL and IPOS) were established using the Pearson's correlation coefficient (r). The analyses were carried out using IBM® SPSS® Statistics 26 Version.

RESULTS

Phase I.

The CDS-IT (Appendix 1), obtained as the result of the back-forward translation process, has been demonstrated to be closely aligned to the original CDS (Table 1).

Phase II.

Characteristics of expert's panel is reported in Appendix 2. According to expert opinions, each item had an adequate content validity. Indeed, all items were deemed relevant as all CVRs were above 0.70 (Table 1). The CDS-IT achieved a S-CVI of 94%, while each item presented a I-CVI of over 89% and a minimum CVR value of 0.78 (Table 1).

Phase III.

Characteristics of the participants.

A total of 101 patients were enrolled, with a mean age of 76 (SD 12) years ranging from 45 to 94 years and 52.5% (53) were female. All patients showed dyspnea in the days prior to enrolment and had an advanced disease, with 63% (64) of them showing a KPS lower than 40 (64). The 39% (39) patients had lung cancer, other diagnoses had lower percentages. The 76% (76) of patients received oxygen therapy. Main comorbidities included chronic obstructive pulmonary disease 26% (26) and heart failure. The average score of CDS-IT was 20 (SD 9). Demographic and Medical Characteristics of Included Patients were presented in Table 2.

Feasibility.

The time for the administration of the CDS-IT scale was 282 (SD 60) seconds. Patients with poorer performance status needed nurse supervision to fill in the questionnaire. There were no items omitted.

Internal Consistency.

Cronbach's alpha of the total score was 0.82 (Table 3). Cronbach's alpha coefficients of the CDS-IT subscales ranged from 0.74 to 0.84 (Table 4). Nine of the corrected item-total correlations were greater than 0.3 and one greater than 0.2.

Construct Validity.

In Table 5, the factor-loading pattern is presented together with the results found by Tanaka et al.(10) The factor solutions corresponded acceptably, but not completely. Three of the six items that were hypothesized to belong to the Factor 1 had a slightly diverse loading pattern in the Italian sample. Items 8, 10, 12 appeared to belong to the Factor 2 rather than Factor 1. In addition, item 4 was very close to both Factors 1 and 2. Pearson's correlations coefficients between the CDS-IT and its factors with the other assessed measures are shown in Table 6. The total CDS-IT score, Factor 1 and Factor 2 showed a moderate to strong correlation with VAS-D ($r=0.68-0.78$). Instead, the correlation between Factor 3 and VAS-D was low ($r=0.22$). The correlation with SpO₂ follows the same trend: a moderate to strong correlation was observed for CDS-IT total score, Factor 1 and Factor 2 [$r=(-0.65)-(-0.75)$] and a low correlation for Factor 3 ($r=-0.17$). The CDS-IT total score, Factors 1 and 2 weakly correlated with EORTC QLQ-C15-PAL and IPOS ($r=0.33 - r=0.40$). No correlations was found between Factor 3 and EORTC QLQ-C15-PAL and IPOS.

DISCUSSION

The study presented the cross-validated Italian version of the CDS questionnaire (*Phase I*) and assessed its content validity among experts in palliative care (*Phase II*). Finally, its feasibility, internal consistency and construct validity were tested in a large sample of patients with advanced life limiting cancer disease (*Phase III*). The findings of *Phase I* and *Phase II* had shown a conceptual equivalence with the original version and a good content validity of all the items. Experts confirmed indeed the absence of ambiguities or items to modify, as reflected by high values of CVR (all items were relevant) and CVI (item feasible and semantically well organized) scores. These results demonstrated that CDS-IT was found to be an acceptable and practicable tool to assess the multidimensional symptoms of dyspnea in clinical practice.

In the *Phase III*, the scale was also confirmed to be feasible on a large sample of patients recruited in two different palliative care settings, hospice and home. The average administration time was around five minutes, an acceptable amount of time for elderly patients with advanced cancer disease, that was slightly higher than those found in previous studies (around 2 minutes).(10, 12, 13) This difference in time could be due to several factors. At first, our study enrolled a sample of frail older adults (mean (SD) age: 76 (12) years old), while in the previous studies (10, 12, 13) the mean age of the participants ranged from 59 to 69 years. Furthermore, the majority of patients (64%) of the present study presented moderate to severe disabilities (Karnofsky Performance Status: 20-40) that could affect the time to fill in the questionnaire, while in the previous studies enrolled participants with better performance status (ECOG Performance status<3).

As the original CDS developed by Tanaka et al. (10) and later cross-validated in English (10, 11), in Swedish (12) and in Hindi and Marathi (13), the CDS-IT is composed by twelve items and three factors describing the sense of effort (Factor 1), anxiety (Factor 2) and discomfort (Factor 3) that dyspnea cause in patients with advanced cancer disease. Although item 1 and 2 showed low item-total correlation (<0.20) as described in Table 3, they were not excluded from the CDS-IT, because their high factor loadings (0.91 and 0.75, respectively) in the structural validity results of Factor 3 (Table 5). These findings demonstrated the multi-dimensionality of the scale by providing the empirical evidence that item 1 and 2, together with item 3, did not measure the same construct assessed by the other items of the scale. Finally, looking at the results of the internal consistency of the three stand-alone factors (Table 4), Cronbach's alpha coefficients and item-total correlations of the three factors indicated acceptable internal consistency (>0.70) and good correlations (0.343-0.752) between each item and the factor score, in line with the previous studies.(10-13)

The results of the confirmatory factor analysis loaded some items differently from the previous studies, particularly for Factor 1 and 2.(10-13) The subjective nature of this symptom together with other elements as different cultural and environmental factors and the advance life-limiting conditions could probably have an important role in the perception of the symptom and could have influenced the factor analysis results.(1, 34, 35) The CDS-IT items 8, 10 and 12 were not loaded on Factor 1, (10) but seemed to belong to the Factor 2. Aspects considered on the Factor 1 (shallow breathing, narrowing and sticking airways) were loaded instead on Factor 2. This could be related to cultural differences; these aspects might evoke, indeed, an emotional reaction. For instance item 4 (shortness of breath), is reported both in the Factor 1 and 2, suggesting both as a physical and anxious sensation. This could indicate that our sample attached greater importance to anxiety caused by dyspnea. Patients may perceive the dyspnea condition much more anxiously and this may be also related to their advanced disease experiences. In the Uronis H. et al. study, three items, including 10 and 12, showed similar loads to our study.(11) Also in Damani A. et al. study, item 10 appeared to belong to the Factor 2 rather than Factor 1.(13) As suggested in Tanaka K. et al. (10), the different dimensions of

dyspnea overlap in such a complex way and are so closely related and they cannot be clearly distinguished in independent factors. On the contrary, Factor 3 (Discomfort) was very well delineated and our findings are similar to previous studies findings.(10-12)

Strong correlation between VAS-D and CDS-IT total score indicated that CDS-IT purposely measures a component of dyspnea. Moderate to strong correlations were confirmed particularly for Factor 1 and Factor 2. In other words, patients who had a high dyspnea perception as measured by VAS-D, also score high in the physical and psychological domain of CDS-IT. These findings confirmed the construct validity of the CDS-IT, in accordance with the previous studies.(10-13) The weak correlation with Factor 3 revealed that VAS-D is a scale that can partially explain the complexity and multidimensionality of dyspnea and further studies are needed to analyze the correlation that interplay between Factor 3 and other dyspnea-related scales to determine its convergence. In our study, as in Tanaka et al. and Uronis et al., we tested the correlation with SpO₂, an objective measure of the degree of blood oxygen saturation linked to the patients' respiratory status. In previous studies, Factors 1 and 2 did not correlate with the SpO₂ (10) and all subscales were weakly correlated with SpO₂ except for anxiety (11), our findings instead showed that the correlations between CDS-IT and SpO₂ mirrored those observed with VAS-D.

Since dyspnea is a relevant symptom that impacts on the patient's essential needs and quality of life of patients in palliative care, EORTC QLQ-C15 Pall and IPOS assessments were included. In accordance with previous studies (11, 12), weak but significant correlations between CDS-IT (Total score, Factor 1 and 2) and EORTC QLQ-C15 Pall and IPOS, revealing a slight but significant link between the impact of the dyspnea symptoms and the quality of life as well as the main concerns reported by patients in palliative care.

The study conducted had some limitations. The test-retest reliability together with the responsiveness to change the minimally clinically important change was not examined in the present study due to the assessment in a single occasion and the lack of longitudinal data. Further studies should investigate these aspects. Despite this, our study is the first to assess the content validity of this scale; moreover, a good number of subjects were recruited despite the frailty condition of the recruited patients in palliative care. In conclusion, our study enriches the literature available, with CDS-IT psychometric properties close to the original and the other cross-cultural validated versions. Its feasibility, internal consistency and validity are satisfactory for clinical practice. The CDS-IT is available to healthcare professionals as a useful tool to assess dyspnea in cancer patients. The validated CDS-IT can be used in a larger sample to determine the prevalence and intensity of dyspnea in patients with advanced disease and its impact on quality of life.

DISCLOSURES

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declare no conflicts of interest relevant to this work.

ACKNOWLEDGMENTS

The authors express their profound gratitude to all the clinical experts of the Hospice and Home Palliative Care of ASST-Rhodense, ASST-Lariana and ASST- Niguarda Hospital, who have offered their time and experience for this study.

REFERENCES

1. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. *Am J Respir Crit Care Med*. 2012;185(4):435-52.
2. Currow DC, Clark K, Mitchell GK, Johnson MJ, Abernethy AP. Prospectively collected characteristics of adult patients, their consultations and outcomes as they report breathlessness when presenting to general practice in Australia. *PLoS One*. 2013;8(9):e74814.
3. Currow DC, Plummer JL, Crockett A, Abernethy AP. A Community Population Survey of Prevalence and Severity of Dyspnea in Adults. *Journal of Pain and Symptom Management*. 2009;38(4):533-45.
4. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. *J Pain Symptom Manage*. 2006;31(1):58-69.
5. Bruera E, Schmitz B, Pither J, Neumann CM, Hanson J. The frequency and correlates of dyspnea in patients with advanced cancer. *J Pain Symptom Manage*. 2000;19:357-62.
6. Escalante CP, Martin CG, Elting LS, et al. Identifying risk factors for imminent death in cancer patients with acute dyspnea *Journal of Pain and Symptom Management*. 2000;20:318-25.

7. Currow DC, Smith J, Davidson PM, et al. Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. *J Pain Symptom Manage.* 2010;39(4):680-90.
8. Gupta D, Lis CG, Grutsch JF. The relationship between dyspnea and patient satisfaction with quality of life in advanced cancer. *Support Care Cancer.* 2007;15(5):533-8.
9. Bausewein C, Booth S, Gysels M, et al. Individual breathlessness trajectories do not match summary trajectories in advanced cancer and chronic obstructive pulmonary disease: results from a longitudinal study. *Palliat Med.* 2010;24(8):777-86.
10. Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y. Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale. *Br J Cancer.* 2000 82(4):800-5.
11. Uronis HE, Shelby RA, Currow DC, et al. Assessment of the psychometric properties of an English version of the cancer dyspnea scale in people with advanced lung cancer. *J Pain Symptom Manage.* 2012;44(5):741-9.
12. Hénoc I, Bergman B, Gaston-Johansson F. Validation of a Swedish version of the Cancer Dyspnea Scale. *J Pain Symptom Manage.* 2006;31(4):353-61.
13. Damani A, Ghoshal A, Salins N, Deodhar J, Muckaden M. Validation of "Cancer Dyspnea Scale" in Patients With Advanced Cancer in a Palliative Care Setting in India. *J Pain Symptom Manage.* 2017;54(5):715-20 e1.
14. Beaton DE, Bombardier C, Guillemin F, Bosi Ferraz M. Guidelines for the Process of Cross-Cultural Adaptation of Self-Report Measures. *SPINE* 2000;25(24):3186–91.
15. Lawshe C. A quantitative approach to content validity. *Pers Psychol* 1975;28:563-75.
16. Lynn M. Determination and quantification of content validity *Nurs Res.* 1986;35(6):382-5.
17. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": A practical guide for grading the cognitive state of patients for the clinician *J Psychiatr Res.* 1975 12:189–98.
18. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer In: MacLeod CM, ed *Evaluation of Chemotherapeutic Agents in Cancer* New York: Columbia University Press. 1949:191-205.

19. Crooks V, Waller S, Smith T, Hahn TJM-. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. *J Gerontol* 1991;46:M139-44.
20. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status scale. An examination of its reliability and validity in a research setting *Cancer* 1984;53:2002-7.
21. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance statu revisited: reliability, validity, and guidelines. *J Clin Oncol.* 1984;2:187-93.
22. Gift AG. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. *Rehabil Nurs.* 1989;14(6):323-5
23. Hu J, Meek P. Health-related quality of life in individuals with chronic obstructive pulmonary disease. *Heart Lung.* 2005;34(6):415-22.
24. Tusman G, Bohm SH, Suarez-Sipmann F. Advanced Uses of Pulse Oximetry for Monitoring Mechanically Ventilated Patients. *Anesth Analg.* 2017;124(1):62-71.
25. Groenvold M, Petersen MA, Aaronson NK, et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. *Eur J Cancer.* 2006;42(1):55-64.
26. Lien K, Zeng L, Nguyen J, et al. Comparison of the EORTC QLQ-C15-PAL and the FACIT-Pal for assessment of quality of life in patients with advanced cancer. *Expert Rev Pharmacoecon Outcomes Res.* 2011(5):541-7.
27. Nunes NAH. The quality of life of Brazilian patients in palliative care: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 PAL (EORTC QLQ-C15-PAL). *Supportive Care in Cancer.* 2014;22(6):1595-600.
28. Bausewein C, Fegg M, Radbruch L, et al. Validation and Clinical Application of the German Version of the Palliative Care Outcome Scale. *Journal of Pain and Symptom Management.* 2005;30(1):51-62.
29. Higginson IJ, Simon ST, Benalia H, et al. Which questions of two commonly used multidimensional palliative care patient reported outcome measures are most useful? Results from the European and African PRISMA survey. *Postgrad Med J.* 2012(88):451-7.

30. Hearn J, Higginson IJ. on behalf of the Palliative Care Audit Project Advisory Group. Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. *Qual Health Care*. 1999(4):219-27
31. Bausewein C, Le Grice C, Simon S, Higginson I. PRISMA. The use of two common palliative outcome measures in clinical care and research: a systematic review of POS and STAS. *Palliat Med*. 2011(4):304-13.
32. Palliative Care outcome Scale. A resource for palliative care. <http://pos-pal.org/>. Accessed 26 Jan. 2016
33. Mokkink LB, Prinsen CA, Patrick DL, et al. COSMIN methodology for systematic reviews of Patient-Reported Outcome Measures (PROMs); user manual. Retrieved 2017 from <http://www.cosmin.nl>. 2017.
34. Bausewein C, Farquhar M, Booth S, Gysels M, Higginson IJ. Measurement of breathlessness in advanced disease: a systematic review. *Respir Med*. 2007;101(3):399-410.
35. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure breathlessness in palliative care? A systematic review. *Palliat Med*. 2007;21(3):177-91.

Table 1. Results of the content validity analysis

Content validity	CVR	I-CVI
Item 1. Can you inhale easily?	1.00 ^a	0.89 ^a
Item 2. Can you exhale easily?	1.00 ^a	0.89 ^a
Item 3. Can you breathe slowly?	0.78 ^a	0.89 ^a
Item 4. Do you feel short of breath?	1.00 ^a	1.00 ^a
Item 5. Do you feel breathing difficulty accompanied by palpitations and sweating?	0.78 ^a	0.89 ^a
Item 6. Do you feel as if you are panting?	1.00 ^a	1.00 ^a
Item 7. Do you feel such breathing difficulty that you do not know what to do about it?	0.78 ^a	1.00 ^a
Item 8. Do you feel your breath is shallow?	0.78 ^a	0.89 ^a
Item 9. Do you feel your breathing may stop?	1.00 ^a	1.00 ^a
Item 10. Do you feel your airway has become narrower?	1.00 ^a	1.00 ^a
Item 11. Do you feel as if you are drowning?	1.00 ^a	1.00 ^a
Item 12. Do you feel as if something is stuck in your airway?	1.00 ^a	1.00 ^a
S-CVI		0.94

I-CVI, item content validity index; S-CVI, scale level content validity index. CVR, content validity ratio.

^a Indicates relevant or adequate item.

Table 2. Demographic and Medical Characteristics of Included Patients (Phase three)

	N=101
Age^a, years	76 (12)
Gender, M/F	48/53
Diagnosis	
Lung cancer ^b	39 (39)
Genitourinary cancer ^b	17 (17)
Breast cancer ^b	11 (11)
Digestive system cancer ^b	15 (15)
Other oncological disease ^b	19 (19)
Comorbidity (Principal)	
Heart failure ^b	18 (18)
COPD ^b	26 (26)
Asthma ^b	5 (5)
Kidney failure ^b	13 (13)
CDS-IT Total^a	20 (9)
CDS-IT Discomfort ^a	7 (3)
CDS-IT Effort ^a	9 (5)
CDS-IT Anxiety ^a	5 (4)
SpO₂^a, %	83 (9)
VAS-D^a	6 (2)
GCS^a	15 (0)

KPS ^a	41 (14)
20 – Very ill ^b	9 (9)
30 – Severely disabled ^b	31 (31)
40 – Disabled ^b	24 (24)
50 – Requires help often ^b	18 (19)
60 – Requiring some help ^b	14 (14)
70 – Caring for self ^b	3 (3)
80 – Normal activity with some difficulty ^b	2 (2)
EORTC QLQ-C15-PAL ^a	32 (8)
IPOS ^a	24 (9)
Oxygen therapy ^a	76 (76)

COPD, chronic obstructive pulmonary disease; CDS-IT, Italian Cancer Dyspnea Scale; SpO₂, peripheral oxygen saturation; VAS-D, Visual Analogue Scale Dyspnea; GCS, Glasgow Coma Scale; KPS, Karnofsky Performance Scale; EORTC QLQ-C15-PAL, European Organization for Research and Treatment of quality of life for cancer in palliative care; IPOS, Italian Palliative care Outcome Scale. ^a Mean (standard deviation); ^b absolute number (percentage).

Table 3. Internal consistency analysis of the CDS-IT

Item	Cronbach's α	Cronbach's α if the item was deleted	Corrected item-total correlation
CDS complete scale	0.818		
Item 1. Can you inhale easily?		0.831	0.128
Item 2. Can you exhale easily?		0.831	0.141
Item 3. Can you breathe slowly?		0.825	0.216
Item 4. Do you feel short of breath?		0.796	0.576
Item 5. Do you feel breathing difficulty accompanied by palpitations and sweating?		0.808	0.431
Item 6. Do you feel as if you are panting?		0.804	0.484
Item 7. Do you feel such breathing difficulty that you do not know what to do about it?		0.792	0.605
Item 8. Do you feel your breath is shallow?		0.793	0.623
Item 9. Do you feel your breathing may stop?		0.798	0.543
Item 10. Do you feel your airway has become narrower?		0.789	0.628
Item 11. Do you feel as if you are drowning?		0.793	0.591
Item 12. Do you feel as if something is stuck in your airway?		0.784	0.693

CDS-IT, Cancer Dyspnea Scale Italian; α , alpha.

Table 4. Internal consistency analysis of the Italian CDS-IT for Factor 1 “sense of effort”, Factor 2 “sense of anxiety” and Factor 3 “sense of discomfort” subscales.

Item	Cronbach's α	Cronbach's α if the item was deleted	Corrected item-total correlation
CDS Effort	0.834		
Item 4. Do you feel short of breath?		0.813	0.589
Item 6. Do you feel as if you are panting?		0.817	0.572
Item 8. Do you feel your breath is shallow?		0.808	0.610
Item 10. Do you feel your airway has become narrower?		0.795	0.660
Item 12. Do you feel as if something is stuck in your airway?		0.765	0.752
CDS Anxiety	0.736		
Item 5. Do you feel breathing difficulty accompanied by palpitations and sweating?		0.772	0.343
Item 7. Do you feel such breathing difficulty that you do not know what to do about it?		0.657	0.563
Item 9. Do you feel your breathing may stop?		0.653	0.566
Item 11. Do you feel as if you are drowning?		0.597	0.653
CDS Discomfort	0.787		
Item 1. Can you inhale easily?		0.600	0.732
Item 2. Can you exhale easily?		0.698	0.639

Item 3. Can you breathe slowly?

0.823

0.523

CDS-IT, Cancer Dyspnea Scale Italian; α , alpha.

Table 5. Exploratory Factor analysis

Item Number and content	Factor 1 ^a	Factor 2 ^b	Factor 3 ^c
Item 1. Can you inhale easily?	-0.03 (-0.29)	0.09 (-0.01)	0.91 (0.91)
Item 2. Can you exhale easily?	-0.06 (-0.16)	0.06 (-0.11)	0.75 (0.94)
Item 3. Can you breathe slowly?	0.00 (-0.18)	-0.06 (-0.17)	0.60 (0.88)
Item 4. Do you feel short of breath?	0.42 (0.69)	0.48 (0.16)	-0.10 (-0.27)
Item 5. Do you feel breathing difficulty accompanied by palpitations and sweating?	0.21 (0.38)	0.33 (0.67)	-0.21 (0.01)
Item 6. Do you feel as if you are panting?	0.96 (0.61)	0.27 (0.35)	-0.02 (-0.25)
Item 7. Do you feel such breathing difficulty that you do not know what to do about it?	0.18 (0.11)	0.66 (0.85)	-0.04 (-0.19)
Item 8. Do you feel your breath is shallow?	0.25 (0.63)	0.61 (0.29)	-0.07 (-0.26)
Item 9. Do you feel your breathing may stop?	-0.01 (0.25)	0.70 (0.81)	0.02 (-0.15)
Item 10. Do you feel your airway has become narrower?	0.16 (0.82)	0.82 (0.16)	0.11 (-0.25)
Item 11. Do you feel as if you are drowning?	0.08 (0.45)	0.85 (0.65)	0.16 (-0.08)
Item 12. Do you feel as if something is stuck in your airway?	0.33 (0.74)	0.78 (0.31)	0.02 (0.01)

^a Factor 1 “sense of effort”; ^b Factor 2 “sense of anxiety”; ^c Factor 3 “sense of discomfort”

Table 6 - Correlations (Pearson Coefficients) between the CDS-IT Total/subscales and VAS-D, SpO₂, EORTC QLQ-C15-PAL, I-POS

	CDS Factor 1 ^a	CDS Factor 2 ^b	CDS Factor 3 ^c	CDS Total
VAS-D	0.678	0.734	0.217	0.780
SpO₂	-0.654	-0.723	-0.170	-0.745
EORTC QLQ-C15-PAL	0.395	0.381	-	0.362
IPOS	0.392	0.388	-	0.326

Only significant Pearson Correlation; ^a Factor 1 “sense of effort”; ^b Factor 2 “sense of anxiety”; ^c Factor 3 “sense of discomfort”; CDS Cancer Dyspnea Scale; VAS-D, Visual Analogue Scale Dyspnea; SpO₂, peripheral oxygen saturation; EORTC QLQ-C15-PAL, European Organization for Research and Treatment of quality of life for cancer in palliative care; IPOS, Italian Palliative care Outcome Scale.

Appendix 1. Translated Italian version of the Cancer Dyspnea Scale (CDS-IT)

CDS-IT

Item 1. Ti senti in grado di inspirare facilmente?

Item 2. Ti senti in grado di espirare facilmente?

Item 3. Sei in grado di respirare lentamente?

Item 4. Senti di avere il fiato corto?

Item 5. Senti che le tue difficoltà respiratorie sono accompagnate da palpitazioni e sudorazione?

Item 6. Hai la sensazione di ansimare?

Item 7. Senti una tale difficoltà respiratoria da non sapere cosa fare?

Item 8. Senti il tuo respiro poco profondo e leggero?

Item 9. Pensi che il tuo respiro possa fermarsi?

Item 10. Senti le tue vie aeree ristrette e che si stanno chiudendo?

Item 11. Ti senti come se stessi per annegare?

Item 12. Senti come se ci fosse qualcosa che blocca le tue vie respiratorie?

Appendix 2. Characteristics of the group of experts, involved in the assessment of content validity (Phase II)

Experts (N = 9)		
Gender ^b	Male	1 (11)
	Female	8 (89)
Age (years) ^a		48 (6)
Profession ^b	Nurse	9 (100)
Education ^b	Bachelor school of Nursing	7 (78)
	Master of Science in Nursing	2 (22)
Work setting ^b	Hospice	3 (33.3)
	Home Palliative Care	3 (33.3)
	University	3 (33.3)
Work experience (years) ^a		13 (9.5)

^a Mean (standard deviation); ^b Absolute number (percentage)

Appendix 1. Translated Italian version of the Cancer Dyspnea Scale (CDS-IT)

CDS-IT

Item 1. Ti senti in grado di inspirare facilmente?

Item 2. Ti senti in grado di espirare facilmente?

Item 3. Sei in grado di respirare lentamente?

Item 4. Senti di avere il fiato corto?

Item 5. Senti che le tue difficoltà respiratorie sono accompagnate da palpitazioni e sudorazione?

Item 6. Hai la sensazione di ansimare?

Item 7. Senti una tale difficoltà respiratoria da non sapere cosa fare?

Item 8. Senti il tuo respiro poco profondo e leggero?

Item 9. Pensi che il tuo respiro possa fermarsi?

Item 10. Senti le tue vie aeree ristrette e che si stanno chiudendo?

Item 11. Ti senti come se stessi per annegare?

Item 12. Senti come se ci fosse qualcosa che blocca le tue vie respiratorie?

Appendix 2. Characteristics of the group of experts, involved in the assessment of content validity (Phase II)

Experts (N = 9)		
Gender ^b	Male	1 (11)
	Female	8 (89)
Age (years) ^a		48 (6)
Profession ^b	Nurse	9 (100)
Education ^b	Bachelor school of Nursing	7 (78)
	Master of Science in Nursing	2 (22)
Work setting ^b	Hospice	3 (33.3)
	Home Palliative Care	3 (33.3)
	University	3 (33.3)
Work experience (years) ^a		13 (9.5)

^a Mean (standard deviation); ^b Absolute number (percentage)